News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
92,160 Results
Type
Article (59634)
Company Profile (12)
Press Release (32495)
Multimedia
Podcasts (19)
Webinars (25)
Section
Business (11817)
Career Advice (240)
Deals (2184)
Drug Delivery (11)
Drug Development (7058)
Employer Resources (21)
FDA (957)
Job Trends (1284)
News (22042)
Policy (3898)
Tag
2027 BioCapital Standard (1)
2027 Biotech Bay Elite (1)
2027 Biotech Beach Elite (1)
2027 Pharm Country Premier (1)
Academia (156)
Accelerated approval (2)
ADA (1)
Adcomms (4)
Allergies (23)
Alliances (2791)
ALS (36)
Alzheimer's disease (265)
Antibody-drug conjugate (ADC) (78)
Approvals (1042)
Artificial intelligence (102)
ASCO (23)
Autoimmune disease (90)
Automation (8)
Bankruptcy (24)
Belgium (1)
Best Places to Work (467)
BIO (8)
Biologics (13)
BIOSECURE Act (2)
Biosimilars (23)
BioSpace Insights (23)
Biotechnology (5)
Bispecific (6)
Bladder cancer (21)
Brain cancer (8)
Breast cancer (102)
Cancer (818)
Cardiovascular disease (61)
Career advice (266)
Career pathing (22)
CAR-T (38)
CDC (4)
CDMO (21)
Cell therapy (122)
Cervical cancer (3)
Clinical research (5902)
Collaboration (308)
Commercialization (11)
Company closure (3)
Compensation (130)
Complete response letters (14)
COVID-19 (454)
CRISPR (21)
C-suite (197)
Cystic fibrosis (7)
Data (1253)
Denatured (3)
Depression (33)
Dermatology (16)
Diabetes (64)
Diagnostics (507)
Digital health (5)
Diversity (1)
Diversity, equity & inclusion (3)
Drug discovery (63)
Drug pricing (13)
Drug shortages (1)
Duchenne muscular dystrophy (19)
Earnings (4252)
Editorial (11)
Employer resources (19)
ESMO (27)
Events (5845)
Executive appointments (135)
Eye disease (4)
FDA (1438)
Fibrodysplasia Ossificans Progressiva (4)
Friedreich's ataxia (2)
Frontotemporal dementia (3)
Funding (213)
Gene editing (35)
Generative AI (7)
Gene therapy (84)
GLP-1 (114)
Government (314)
Grass and pollen (1)
Guidances (33)
Healthcare (838)
Hematology (13)
HIV (10)
Huntington's disease (4)
Idiopathic pulmonary fibrosis (2)
IgA nephropathy (18)
Immunology and inflammation (52)
Immuno-oncology (15)
Indications (30)
Infectious disease (505)
Inflammatory bowel disease (25)
Inflation Reduction Act (1)
Influenza (17)
Intellectual property (29)
Interviews (41)
IPO (1009)
IRA (3)
Job creations (598)
Job search strategy (216)
JPM (4)
Kidney cancer (11)
Kidney disease (15)
Labor market (115)
Layoffs (185)
Leadership (13)
Legal (856)
Licensing (9)
Liver cancer (2)
Longevity (5)
Lung cancer (115)
Lung diease (1)
Lymphoma (79)
Machine learning (13)
Management (9)
Manufacturing (149)
Marketing (1)
MASH (16)
Medical device (613)
Medtech (640)
Mergers & acquisitions (1329)
Metabolic disorders (161)
mRNA (32)
Multiple sclerosis (59)
Multispecific (2)
Netherlands (4)
Neurodegenerative disease (53)
Neuropsychiatric disorders (17)
Neuroscience (515)
NextGen: Class of 2026 (337)
Non-profit (75)
Now hiring (69)
Obesity (75)
Opinion (33)
Ovarian cancer (27)
Pain (27)
Pancreatic cancer (61)
Parkinson's disease (59)
Partnered (3)
Patents (75)
Patient recruitment (108)
Patient selection (14)
Peanut (4)
People (3540)
Peptides (3)
Pharmaceutical (1)
Pharmacy benefit managers (3)
Phase 1 (1931)
Phase 2 (2365)
Phase 3 (1763)
Pipeline (1697)
Policy (32)
Postmarket research (773)
Preclinical (1433)
Press Release (2)
Prostate cancer (35)
Psychedelics (17)
Radiopharmaceuticals (54)
Rare diseases (147)
Real estate (456)
Recruiting (9)
Regenerative medicine (4)
Regulatory (3478)
Reports (27)
Research institute (125)
Resumes & cover letters (29)
Rett syndrome (7)
RNA editing (2)
RSV (15)
Schizophrenia (13)
Series A (36)
Series B (30)
Sickle cell disease (13)
Special edition (15)
Spinal muscular atrophy (14)
Sponsored (10)
Startups (251)
Stomach cancer (1)
Supply chain (13)
Tariffs (19)
The Weekly (16)
Vaccines (408)
Venture capital (20)
Weight loss (44)
Women's health (19)
Worklife (11)
Date
Today (7)
Last 7 days (71)
Last 30 days (359)
Last 365 days (4386)
2026 (3789)
2025 (2807)
2024 (2545)
2023 (2374)
2022 (2970)
2021 (3222)
2020 (2670)
2019 (2030)
2018 (1484)
2017 (4003)
2016 (4925)
2015 (4735)
2014 (4822)
2013 (5471)
2012 (5425)
2011 (5105)
2010 (4988)
Location
Africa (441)
Alabama (4)
Arizona (19)
Arkansas (3)
Asia (6547)
Australia (1637)
California (1746)
Canada (464)
China (231)
Colorado (48)
Connecticut (91)
Delaware (70)
Europe (24304)
Florida (202)
Georgia (37)
Hawaii (1)
Illinois (112)
India (19)
Indiana (67)
Iowa (5)
Japan (77)
Kansas (3)
Kentucky (6)
Louisiana (3)
Maine (3)
Maryland (163)
Massachusetts (1367)
Michigan (37)
Minnesota (58)
Missouri (10)
Montana (4)
Nebraska (5)
Nevada (19)
New Hampshire (14)
New Jersey (472)
New Mexico (1)
New York (408)
North Carolina (178)
North Dakota (2)
Northern California (938)
Ohio (41)
Oklahoma (2)
Oregon (3)
Pennsylvania (301)
Puerto Rico (2)
Rhode Island (7)
South America (381)
South Carolina (8)
Southern California (619)
Tennessee (22)
Texas (193)
United States (5469)
Utah (31)
Virginia (30)
Washington D.C. (14)
Washington State (106)
Wisconsin (17)
92,160 Results for "recipharm ab".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Immunology and inflammation
AB Science ends 3 studies in multiple sclerosis, other immune conditions
The trials, which were testing the tyrosine kinase inhibitor masitinib, had previously been paused. AB Science’s decision not to resume them was a matter of prioritization, not safety, the biotech said.
July 13, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Bulletin from the Extraordinary General Meeting of Spago Nanomedical AB
October 22, 2026
·
1 min read
Press Releases
Announcement From the Extra General Meeting in Biovica International AB
September 30, 2026
·
3 min read
Press Releases
Notice Of Extraordinary General Meeting in Spago Nanomedical AB (PUBL)
September 21, 2026
·
30 min read
Press Releases
Announcement from the Annual General Meeting in Biovica International AB 2026
September 16, 2026
·
9 min read
Press Releases
Arbutus Announces FDA Clinical Hold is Lifted on IND Application for AB-101, an Oral PD-L1 Inhibitor
October 22, 2026
·
4 min read
Press Releases
New Number of Shares and Votes in IRLAB Therapeutics AB
July 31, 2026
·
1 min read
Press Releases
Notice Of Annual General Meeting in Biovica International AB 2026
August 14, 2026
·
75 min read
Press Releases
Alligator Bioscience AB Reports Financial Results for The Period 1 January - 30 September 2026 and Provides a Business Update
October 22, 2026
·
5 min read
Press Releases
AB Science today reports its revenues for the first half of 2026 and provides an update on its activities
October 12, 2026
·
21 min read
1 of 9,216
Next
